Effect of Multidisciplinary Dyslipidemia Educational Program on Adherence to Guidelines Directed Medical Therapy in Saudi Arabia
4
Citation
25
Reference
10
Related Paper
Citation Trend
Abstract:
A prospective cohort study was conducted. The practice in three clinics, cardiology, primary care, and endocrine, was assessed by data collection including demographic information, lipid profile (HDL, triglyceride, LDL, total cholesterol), and lipid-lowering drugs. All consecutive patients with hyperlipidemia were included. Extensive educational sessions have been implemented at the beginning of the study. Morisky score was assessed at the initial visit and months 3 and 9 to assess the medicatioKeywords:
Dyslipidemia
Hyperlipidemia
Demographics
Fibrinopeptide A (FPA) levels were measured in a group of 130 controls and patients with various types of primary hyperlipidemia to investigate whether an increased steady state level of thrombin activity is present in hyperlipidemic patients. In a subset of 56 subjects, levels of clotting factors II, VII, and X were measured as well. FPA levels in hyperlipidemic patients were not significantly different from those of control subjects. Furthermore, on multiple regression analysis, no significant relationships were found between FPA levels and the concentrations of serum cholesterol or triglyceride, or log triglyceride levels. Statistically significant relationships were found between all three clotting factor levels and triglyceride concentration. The correlation coefficients for these relationships, however, were low, so that the correlations are of questionable pathophysiological significance. A weak relationship also was found between the plasma levels of cholesterol and of factor II. Thus, although small increases in various clotting factors may be found in patients with hyperlipidemia, plasma FPA levels are normal. These data indicate that hyperlipidemia is not associated with a steady state of increased thrombin activity in vivo in humans.
Hyperlipidemia
Clotting factor
Cite
Citations (7)
Objective To explore the effect of extracts of barley on lowering serum lipid in hyperlipidemia population. Methods Totally 106 hyperlipidemia volunteers were randomly divided into test group and control group according to contents of serum lipid.The volunteers in test group were orally administered with extracts of barley on 45 successive days.Before and after the test,serum total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDL-C) and the indexes of safety were determined. Results After the test,the levels of TC and TG in test group decreased significantly,and the decreasing rates of TC and TG were 10.64% and 16.65%,respectively.After the test,there were statistically significant differences in the levels of TC and TG between control group and test group,also between before and after the test in test group.The level of HDL-C was increased by 0.11 mmol/L,and there was no statistically significant difference between test group and control group(P0.05).No significant change was found in all the indexes of safety before and after the test. Conclusions Extracts of barley has serum lipid-lowering effects in hyperlipidemia population.
Hyperlipidemia
High-density lipoprotein
Serum cholesterol
Cite
Citations (1)
The effects of niceritrol on serum lipids and apolipoproteins were investigated in 29 patients with hyperlipidemia for 12 weeks. Total cholesterol was decreased significantly by 5.4% after the treatment without lowering HDL cholesterol. The atherogenic index was decreased significantly. Serum triglyceride had a tendency to decrease but not significantly. In 13 patients with hypertrigly-ceridemia (more than 150mg/dl of triglyceride), serum triglyceride was decreased by 20%. The apolipoproteins A-I, A-II and B were decreased significantly. There were no effects on apolipoprotein C-II and C-III. Apolipoprotein E decreased significantly. Flushing occurred in 5 patients with hyperlipidemia, but other major side effects did not occure. These results suggested that niceritrol was effective in treatment of patients with hyperlipidemia.
Hyperlipidemia
Cite
Citations (0)
Objective To study the effects and safety of Xuezhikang in elderly patients with hyperlipidemia.Methods Sixty patients were observed for 8 weeks with auto control method.Results Xuezhikang could markedly decrease the level of triglyceride and serum total cholesterol in elderly patients,especially triglyceride.Its effects were the same as other tatin drug.After observing 8 weeks,no side effects were found in clinic and biochemistry.Conclusion It is a safe and effective medicine in treating elderly patients with primary hyperlipidemia.
Hyperlipidemia
Cite
Citations (0)
Hyperlipidemia
Cite
Citations (1)
Dyslipidemia substantially contributes to the risk of cardiovascular diseases. The polyherbal formulation has been a traditional therapeutic strategy used to treat dyslipidemia. This study was designed to evaluate the effects of a novel herbal medicine called “GANMO” on an experimental animal model with endogenous dyslipidemia and exogenous dyslipidemia. In the endogenous hyperlipidemia model, rats were previously treated with GANMO tablets and intraperitoneally injected with poloxamer 407 to induce hyperlipidemia. In the exogenous hyperlipidemia model, rats were given oral administration of oil-cholesterol mixture and GANMO for 4 consecutive weeks. Serum lipid profiles were assessed at all experimental animals. In both models, GANMO at both doses significantly decreased the serum total cholesterol (TC) level and non-high-density lipoprotein (HDL) cholesterol level as compared with the model group. HDL cholesterol levels increased in rats with high doses of GANMO compared to those with low doses. GANMO at both doses substantially reduced TG level in the endogenous hyperlipidemia model. In conclusion, GANMO tablets posed a positive effect on serum lipid modulations in dyslipidemia models.
Dyslipidemia
Hyperlipidemia
Lipid Profile
Cite
Citations (2)
Hyperlipidemia
Cite
Citations (0)
This is the first study to examine the long-term effect of 5-aminolevulinic acid mainly on serum lipoproteins in dogs with hyperlipidemia. We studied 5 Miniature Schnauzer cases whose fasting serum total triglyceride and very-low-density lipoprotein of triglyceride levels were extremely high (635 ± 116 and 520 ± 92 mg/dL, respectively). Although the total cholesterol values were normal, the very-low-density lipoprotein of cholesterol level was high (49 ± 7 mg/dL). Each dog received a 5-aminolevulinic acid supplement (5 mg/day) orally for 6 months. The mean values of total triglyceride, very-low-density lipoprotein of both triglyceride and cholesterol decreased significantly after the treatment period (319 ± 29, 245 ± 18, and 27 ± 2 mg/dL, respectively, P < 0.05). Our present results may present evidence that 5-ALA administration contributes to improvement of hyperlipidemia in Miniature Schnauzer.
Hyperlipidemia
High-density lipoprotein
Low-density lipoprotein
Cite
Citations (4)
Objective To study the characteristics of dyslipidemia and phenotyping of hyperlipidemia.Methods The four lipid items and LP(a) level of 1 500 cases of the professional population were investigated.The characteristics of dyslipidemia and phenotyping of hyperlipidemia were studied.Results Only 45.2% had suitable TC,TG,LDL-C and HDL-C levels,and 53.0% had suitable TC and TG levels in all subjects.The detection rate of hyperlipidemia type Ⅱa(10.7%) was more higher than that of type Ⅳ(5.6%) and type ⅡB(1.3%).The detection rate of simultaneous high Lp(a) and LDL-C of young males was significantly higher than that of females.There wasn't statistical difference of the detection rate between males and females in other age groups.Conclusion Lipid reduction treatment should be emphasized on regulating TC and LDL-C levels.Postmenopause females and young males should pay attention to earlier prevention and treatment of dyslipidemia.
Dyslipidemia
Hyperlipidemia
Lipid Profile
Cite
Citations (0)
This study was aimed to compare the effects of Salvia Sharifi and Salvia Virgata on serum lipids and histopathology of liver in hyperlipidemic rats. Forty male adult Wistar rats were distributed into four groups as follow: (1) control, (2) hyperlipidemic rats, (3) hyperlipidemic rats received hydroalcoholic extract of S. Virgata (200 mg/kg bw) and (4) hyperlipidemic rats received hydroalcoholic extract of S. Sharifi (200 mg/kg bw). A high-fat diet was administered to rats for one month.Then, two rats were selected from each diet group and hyperlipidemia was confirmed by measurement of serum triglyceride and serum cholesterol levels. Groups 3&4 were orally treated by S. Virgata and S. Sharifi respectively for 21 days. At the end of the experiment, blood samples were obtained by heart puncture and used to determine serum triglyceride, cholesterol, HDL and LDL levels and liver specimens were obtained for histopathological investigations. The data were analyzed by one-way ANOVA and Tukey's post hoc test. The results showed that S. Sharifi extract significantly reduced serum triglyceride, cholesterol and LDL levels and increased serum HDL compared to untreated hyperlipidemic rats. Treatment with S. Virgata reduced serum triglyceride, cholesterol and LDL levels but serum HDL of rats in this group had no significant effect in comparison to hyperlipidemic group. In addition, S. Sharifi extract decreased hepatic lesions in comparison to hyperlipidemic rats received S. virgata. These results showed the protective effect of S. Sharifi and S. Virgata extracts on hyperlipidemia-induced liver injury and this protection was more pronounced in the group received S. Sharifi.
Hyperlipidemia
Salvia
Histopathology
Lipid Profile
Cite
Citations (0)